Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine hydrochloride + triamcinolone acetonide + povidone-iodine + lidocaine
- Development stage
- Unknown
- Lead developer
- Asclemed USA
- Modality
- Small Molecules
- Administration
- Parenteral, Epidural, Percutaneous, Ophthalmic
01
Overview
A multi-component **small molecule combination product** comprising **bupivacaine hydrochloride**, **lidocaine**, **triamcinolone acetonide**, and **povidone-iodine**, identified in public sources as **BLT-25 KIT** and developed by **Asclemed USA**. The product is intended for **local and regional anesthesia and analgesia**. Its pharmacology combines local anesthetic sodium-channel blockade from bupivacaine and lidocaine, anti-inflammatory glucocorticoid activity from triamcinolone acetonide, and antiseptic activity from povidone-iodine. Reported administration approaches include infiltration and regional neuraxial or nerve-block use such as perineural, caudal, epidural, and retrobulbar administration. Public context provided indicates it is an **unapproved drug product** that has **not been found by the FDA to be safe and effective** and whose labeling has **not been approved by the FDA**.
- Other names
- bupivacaine hydrochloride + triamcinolone acetonide + povidone-iodine + lidocaine
02
Targets
NaV (Voltage-gated sodium channels)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on bupivacaine hydrochloride + triamcinolone acetonide + povidone-iodine + lidocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine hydrochloride + triamcinolone acetonide + povidone-iodine + lidocaine.